Respiratory syncytial virus (RSV) is one of the main reasons leading to hospitalization among young children worldwide and each year, an estimated 101,000 children below the age of 5 years die due to RSV infections. Since the end of 2022, the use of a long-acting monoclonal antibody (nirsevimab) in infants as means of passive immunization against RSV has been allowed in the European Union and European Economic Area (EU/EEA). However, only a few countries in the EU/EEA started using nirsevimab prior to the RSV season 2023/24.
You may also be interested in:
Babies who are breastfed, or partially breastfed, for more than six months are less likely to be given sugar-sweetened drinks and sweet or salty snacks [...]
Increased numbers of preterm births, higher incidence of respiratory disease and death, and more children in hospitals are some of the stark health outcomes the [...]
After a one-year interdisciplinary therapy program that included clinical, nutritional, psychological and exercise counseling, a group of 22 obese adolescents not only lost weight but [...]